Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular analysis of CRC in patients with Primary Sclerosing Cholangitis (PSC) and Inflammatory Bowel Disease (IBD)

ABSTRACT: Patients with both primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) run a 10-fold increased risk of developing colorectal carcinoma (CRC) compared to patients with IBD only. It is unknown which mucosal defects are causing this increased risk. The aim of this study was to investigate which molecular changes give rise to CRC in patients with PSC-IBD, and whether changes occur already in non-dysplastic mucosa.

PROVIDER: EGAS00001004497 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis [scData]

Project description:Primary sclerosing cholangitis (PSC) is an autoimmune-like disease of the bile ducts that co-occurs with inflammatory bowel disease (IBD) in almost 90% of cases. Colorectal cancer is a major complication of patients with both PSC and IBD, and these patients are at a much greater risk compared to patients with IBD without concomitant PSC. Combining flow cytometry, bulk and single cell transcriptomics, and T- and B-cell receptor repertoire analysis of right colon tissue from PSC, IBD, and healthy controls we identified a unique adaptive inflammatory transcriptional signature associated with greater risk and shorter time to dysplasia specifically in patients with PSC. This inflammatory signature is characterized by antigen-driven IL-17A+ Foxp3+ CD4 T-cell and an expansion of IgG-secreting B-cell responses. These data results suggest that the mechanisms that drive the emergence of dysplasia in of PSC and IBD dysplasia are distinct and provide molecular insights to guide prevention of colorectal cancer in PSC.

2023-04-30 | GSE230568 | GEO

Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis [bulk RNASeq]

2023-04-30 | GSE230524 | GEO

Ursodeoxycholic Acid (UDCA) in Preventing Hepatobiliary and Colorectal Malignancy in Surveillance Patients with Primary Sclerosing Cholangitis (PSC)

Project description:Primary objectives: (i) To assess in incidence of biliary malignancy as assessed by surveillance MR/MRCP in patients with PSC with and without response to UDCA(ii) To assess in incidence of colorectal malignancy as assessed by surveillance colonoscopy in patients with PSC with and without response to UDCA Primary endpoints: - any hepatobiliary malignancy including low-grade dysplasia detected by surveillance MRCP- any colorectal malignancy including low-grade dysplasia detected by surveillance colonoscopy

| 2534809 | ecrin-mdr-crc

Tissue-dependent transcriptional and bacterial associations in primary sclerosing cholangitis-associated inflammatory bowel disease

Project description:Using RNA-seq we aimed to characterise the transcriptome of patients with PSC-associated IBD relative to patients with ulcerative colitis or healthy. This was performed across multiple tissue locations in order to define tissue-dependent associations.

2021-01-01 | E-MTAB-9658 | biostudies-arrayexpress

Serum and bile proteomics reveal candidates for new noninvasive serum markers of primary sclerosing cholangitis and of risk of disease progression and biliary neoplasia.

Project description:Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by biliary strictures, cholestasis, and an increased risk of cholangiocarcinoma (CCA). Here, we have used label-free quantitative proteomics to analyze serum and bile samples from non-PSC controls and PSC patients, as well as from PSC patients divided into groups according to endoscopic retrograde cholangiography score (with a score of >4 indicating advanced disease) and presence or absence of biliary dysplasia/CCA. Further analyses subsequently identified multiple candidates of new noninvasive serum markers for the diagnosis of PSC, as well as new markers for the prediction of the risk of disease progression and biliary neoplasia for patients already diagnosed with PSC.

2022-08-03 | PXD026693 | Pride

Serum and bile proteomics reveal candidates for new noninvasive serum markers of primary sclerosing cholangitis and of risk of disease progression and biliary neoplasia (BILE)

2022-08-03 | PXD026694 | Pride

Il-17 Signaling in Primary Sclerosing Cholangitis Patient-Derived Organoids

Project description:The pathogenesis of primary sclerosing cholangitis (PSC) is unclear, although studies implicate IL-17A as an inflammatory mediator in this disease. However, a direct assessment of IL-17 signaling in PSC cholangiocytes is lacking. Cholangiocytes obtained from PSC and non-PSC patients by endoscopic retrograde cholangiography (ERC) were cultured as extrahepatic cholangiocyte organoids (ECO). The ECO were treated with vehicle or IL-17A and assessed by NanoString analysis, single cell RNA sequencing (scRNA-seq), and whole genome sequencing (WGS). The secretome was assessed by Olink analysis. Unsupervised clustering of all integrated scRNA-seq data identified 8 cholangiocyte clusters which did not differ between non-PSC and PSC ECO. However, PSC ECO cells demonstrated a much more robust response to IL-17 treatment, noted by an increased number of differentially expressed genes (DEG) after the treatment with IL-17A, compared to non-PSC ECO. After rigorous filtering, WGS identified the presence of somatic mutations that were shared between PSC ECO. However, no somatic mutations dysregulating genes in the IL-17 pathway were identified. The secretome of PSC ECO contained more abundant chemokines and cytokines under basal conditions and following IL-17A stimulation when compared to non-PSC ECO. In conclusion, PSC and non-PSC patient derived ECO respond differently to IL-17 stimulation regardless of mutational status, suggesting a change in epigenetic regulation and the implication of this pathway in the pathogenesis of PSC.

2024-01-29 | GSE239283 | GEO

PSC-IBD mucosal omics

Project description:PSC-IBD mucosal biology

| PRJEB32208 | ENA

PSC-IBD mucosal biology

Project description:PSC-IBD mucosal biology

| PRJEB32359 | ENA

Circulating miRNA signature in bile of pateints with primary sclerosing cholangitis (PSC) vs cholangiocarcinoma (CC)

Project description:RNA was isolated from bile of pateints with PAS or CC and global microRNA profiling was done using miRNome microRNA Profiler QuantiMir Human PCR Array (#RA660A-1, version 15; BioCat, Heidelberg, Germany) Three arrays were performed for the PSC group with pooled RNA from n = 5 patients each and two arrays for the CC group with pools of RNA from n = 4 patients each

2015-09-02 | E-GEOD-72593 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data